The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ESH 2017 | Highly targeted medication for AML
There have been large strides in the treatment of leukemia; however, current methods lack specificity. Speaking from the International Conference on Acute Myeloid Leukaemia 2017, Estoril, Portugal by the European School of Hematology (ESH), Andrew Wei, MBBS, PhD, FRACP, FRCPA from Alfred Hospital and Monash University, Melbourne, Australia discusses the use of targeted medication to inhibit anti-apoptotic proteins and how this could reduce toxicity.
